Serum KL-6 as a marker of disease progression in SSc-ILD
C. Stock (London, United Kingdom), R. Hoyles (London, United Kingdom), C. D'Accord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), C. Campochiaro (London, United Kingdom), J. Donovan (London, United Kingdom), L. Mori (London, United Kingdom), T. Maher (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), V. Ong (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom)
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Stock (London, United Kingdom), R. Hoyles (London, United Kingdom), C. D'Accord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), C. Campochiaro (London, United Kingdom), J. Donovan (London, United Kingdom), L. Mori (London, United Kingdom), T. Maher (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), V. Ong (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom). Serum KL-6 as a marker of disease progression in SSc-ILD. 3664
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011
Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017
Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis Source: Eur Respir J 2014; 43: 1530-1532 Year: 2014
KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019
Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008
Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005